FDA: Immune Tx Monotherapy in Bladder Ca May Worsen Survival
(MedPage Today) -- Pembrolizumab, atezolizumab trials stop enrolling patients with low PD-L1
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: International Medicine & Public Health